Clinical Trial Detail

NCT ID NCT02576977
Title Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

multiple myeloma

Therapies

Pomalidomide

Pembrolizumab

Dexamethasone

Age Groups: adult

No variant requirements are available.